Please assess the completion status of the following clinical trial:

Trial Title: Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cancer~* Outpatient status at the time of study entry~* 18 years of age or older~* Life expectancy of at least 1 month~* Regular access to a telephone (for safety reasons)~* Reliable transportation to follow-up visits~* Caregiver observation available for 24 hours after the dose~* Histologically-proven malignancy~* Depression score of \>11 on the Hospital Anxiety and Depression Scale (HADS)~* Provision of informed consent~* Able to complete the patient questionnaires alone or with assistance~* Able to speak and read English~* May receive other psycho-active medications while on the study i.e. opiates, except as defined within the exclusion criteria~* May receive psychotherapy from an outside provider at the beginning and/or during the course of the study~Exclusion Criteria:~* Obvious cognitive dysfunction or Mini Mental Status Exam score \<20~* Antidepressants started or dose changed within 8 weeks of the beginning of the study or during the study~* Benzodiazepines prescribed for psychiatric indications that have been started or dose change within 2 weeks of the beginning of study enrollment~* Suicidal ideation or a suicide attempt within the last year~* Patients with current or past psychosis not from delirium~* Females who are pregnant or nursing~* Unable to take oral medications~* Primary or metastatic brain malignancy~* Gastrointestinal tract obstruction~* Prior adverse reaction to or other contraindication to ketamine~* Substance abuse or dependence, as defined by Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria, within the last 90 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Single dose of ketamine (0.5 mg/kg)
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).